Gaurav

New research tracks Oklahoma student achievement's 'long decline' to 48th in nation tulsaworld.com/news/local/edu… via @tulsaworld

Dr. Paul Kincade devoted his life to medical research, spending his entire career probing the mysteries of the human immune system. That commitment continued upon his death, with the former VP of research at OMRF making a $500,000 estate gift to OMRF. omrf.org/2026/02/23/res…

OMRF dedicated the Research Tower's fifth floor as the Meinders Center for Neurodegenerative Research, thanks to a $8.25 million gift by Herman Meinders and the Meinders Foundation. The new space will serve as a hub for studying brain diseases in Oklahoma. omrf.org/2026/02/16/omr…

Harrison and Elaine Levy have made a $1 million gift to the Oklahoma Medical Research Foundation to support Alzheimer’s research. To honor that gift, on Wednesday OMRF dedicated the Levy & Ray Family Laboratory for Alzheimer’s Research. omrf.org/2026/02/12/1-m…

Thank you,@SanjeevSaGa @sumeetpalsingh8 @SNU_NatScience, for having me and for the warm hospitality! Really enjoyed discussing our work with the faculty and students today. SNU has a stunning campus and houses one of the largest zebrafish facilities in India, truly impressive!

A powerful new technology developed at OMRF could dramatically speed up the process of diagnosing rare genetic diseases. Read more: omrf.org/2026/02/03/omr…

@ShengJiaLin9413 @AmericanAir Yes!

@varshneylab @AmericanAir Not again 😩

One downside of living in Oklahoma is that you are stuck with @AmericanAir: pathetic service and rude staff.

Grateful to ORIP/NIH @NIH_ORIP and the Presbyterian Health Foundation @phfokc for supporting this research.

TCBE-Umax delivers: ✓ 2x higher efficiency ✓ Works across diverse sequence contexts ✓ Minimal indels ✓ Expanded PAM options for hard-to-target sites

Our paper on TCBE-Umax is out in @natBME! We developed these high-efficiency cytosine base editors for zebrafish, enabling rapid functional testing of disease variants. This work is led by a talented scientist @qinwei007007 nature.com/articles/s4155…

@mbeisen @biorxivpreprint Nature should launch Nature Red or Pink.

In light of the launch of Cell Press Blue cell.com/cell-press-blu…, I want to let everyone know about @biorxivpreprint Blue

@manorlaboratory Best wishes!

@pranamanam Congratulations Pranam! Best wishes for a new phase of your life.

Just got back from my wedding (and honeymoon 🇫🇷) -- the most magical (and relaxing) time of my life! To share our special day with my students, past and present, was incredible (pics below)! 🥰 Also, SO MUCH has happened in AIxBio while I gone! 🫨 I'll share my thoughts! 👇 But first, I can't express how much emotional it is (even with a young lab), to see generations of your team come together. @njakimo, my own closest mentor at MIT during undergrad/grad school, Sabrina, my first undergrad when I was a PhD student, my three former undergrads during my postdoc @Harvard: @garykbrixi (Evo2), @kalyanmpalepu @bhat_suhaas (Rhodes), and my amazing current/past students @DukeU and @Penn! 🥰 Even little @_sophia_tang_ took time away from her many projects! ☺️ I am so fortunate to have the best, most brilliant students in the world, who are all are such wonderful human beings. 💛 Okay, so back to the field! This week we saw BoltzGen, ODesign, OpenFold, Pearl -- all of which look very strong on all-atom benchmarking, prediction, and design tasks. Huge shoutout to @HannesStaerk and the Boltz team especially for getting experimental validations too! 🧑‍🔬 In the past month, many other models have come out: ProteinHunter for hallucination-based design, multimodal pLMs like Odyssey, and a month back, ProDiT from @aiproteins and Bowen (so so many more that I can't all highlight)! The field is moving (stressfully) quick in the representation/prediction/design tasks in both sequence and structure space. 🌬️ Not all of these tools can or will get used (there's just too many), but the hype-ier you can be, the more adoption you probably will get. That's just the (IMO slightly depressing) state of our field. 😔 Just gotta play the game, right? We've taken a slightly different route: my lab develops therapeutics internally ourselves (going from theory to in vivo). We know binding/interaction is important (and local) but you just can't ignore other key properties which are more global/contextual: half-life, solubility, toxicity, immunogenicity. ⚕️ Who cares if you can bind if you can't even get your molecule thru pre-clinical studies! That's why, over the past year, @_sophia_tang_ @TongChen321 @yinuo_z98 @SophieVincoff and the team, have been developing multi-objective-guided discrete models like PepTune, MOG-DFM, TR2-D2, AReUReDi (and more soon) that generate Pareto-optimal designs (we've done DNA, mRNA, proteins, and of course, peptides)! ⚖️ Eventually, folks using structure have to figure it out, but when you're only modeling local interactions (and you have to guide generation with global properties), there's bound to be a mismatch. 🙅‍♂️ And that 10 year promise to cure all diseases from @demishassabis? Not happening (not like it was ever going to 🙄). So where IS the field trending to for the next few years? Clearly in two directions: dynamics and cell state perturbation (please stop calling it Virtual Cells -- what does that even mean 😑) -- both of which should give more "context" to design. And both of these directions NEED advancements in theory (for example, in transition path sampling, my favorite of which are coming from @AlexanderTong7, @bose_joey, @mmbronstein, @ask1729's groups). From us, you've seen @_sophia_tang_ @yinuo_z98's work on our new Schrödinger Bridge frameworks, but more are coming soon to model intermediate and terminal states (cell and protein states) even better! 🫡 Here's the thing, though, these problems don't just need data, they need GROUND-TRUTH DATA. And for dynamics, that can't only be MD data (that's not real and still has all of the real-world inaccuracies of PDB-based structures). For now, to develop algorithms, it's fine (we use it -- it's all we have), but we must allow experimentalists the time to develop methods/assays to capture dynamics in cells/physiologically relevant environments. Otherwise, we will mistakenly claim this problem to be solved and folks will just jump to the next problem. A classic tendency of AIxBio that we have to stop doing. 🛑 Same goes for cell perturbation prediction/design. Single cell data is amazing for hypothesis generation and studying biology at scale (@GametoGen's tech wouldn't be possible without it!). But for ground-truth modeling? NO. In a given cell x gene matrix, like half the genes have counts of 0! You're telling me that's the full state of a cell?🤦‍♂️ And don't get me started on single cell spatial/epigenomics or other newer modalities with even sparser data modes! The folks hyping single cell foundation models and virtual cells need to take a breather. 🫥 We don't need a next "AlphaFold" moment, but we do need to solve this problem well: predicting and designing state perturbations are incredibly important challenges for bioengineering that we can't just hand-wave. One word: PATIENCE. 🫷 AIxBio isn't patient. Yes, we need to move fast because we can provide great therapies and solutions to many global problems. But if we move TOO fast, our work will be cool, sure, but meaningless. Work with experimentalists and give them space/time to hone their methods/instrumentation/data generation, and you, the algorithm folks, will benefit from the data, and the loop of benefit begins, and we create meaningful outputs! ♻️ And finally, let's CHILL with the hype. ❄️ Please. We're better than this. No model needs a 4k hype vid or launch party. This goes for some VCs too: on the same day you won't write a $500k seed check to a small company with strong pre-clinical data on an asset b/c you don't like the target or some random reason, you'll throw like $500M at a hyped-up AIxBio company -- bc idk, vibes? 💁 Look, let us show our models works, get experimentalists to use them, push good, optimized molecules into the clinic/field, and always be cognizant that we still have a long way to go. We'll get there. For me, I'm just grateful to have such a wonderful team to do it with. 😇

@npho_ Are you making barcode app?😂

Since many desktop apps are Electron apps of the original websites, is it more efficient to just launch your desktop apps as tabs instead? Anyone have any data to suggest one work set up versus the other?

@mfwangler @HGGAdvances Congrats Michael and team!

Our paper focused on SLC6A1 is out in @HGGAdvances

@TheRealDrOLab Yes, this year's app is horrible!

I think the biggest fail in the last 20 years of #ashg25 is this horrible app. Basically useless. I’d rather have the old program book. #ashg2025

@anshulkundaje @arcinstitute Congratulations, Anshul!

Grateful to the @arcinstitute for the Ignite Award, especially in these challenging times. Congrats to all the other awardees including the two new core members & the 7 innovation awardees. Look forward to continue collaborating with several teams at Arc.

Sneak peek to our largest fundraising event of the year happening this weekend!🌻🎸🍷 241 is a private, two-day event benefiting medical research in Oklahoma. Thank you to our committee members and sponsors who make this event possible! 👏

The new findings by Drs. Courtney Griffin and Eric Ma hold the potential for developing drugs to prevent or treat diabetic retinopathy and retinopathy of prematurity (ROP), both of which damage the retina and can lead to blindness. Read more: omrf.org/2025/09/25/omr…